Patient-Derived Orthotopic Xenograft (PDOX) Mouse Models of Primary and Recurrent Meningioma.
HDAC inhibitor
PDOX
meningioma
modelling
xenograft
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
05 Jun 2020
05 Jun 2020
Historique:
received:
03
05
2020
revised:
26
05
2020
accepted:
01
06
2020
entrez:
11
6
2020
pubmed:
11
6
2020
medline:
11
6
2020
Statut:
epublish
Résumé
Meningiomas constitute one-third of all primary brain tumors. Although typically benign, about 20% of these tumors recur despite surgery and radiation, and may ultimately prove fatal. There are currently no effective chemotherapies for meningioma. We, therefore, set out to develop patient-derived orthotopic xenograft (PDOX) mouse models of human meningioma using tumor. Of nine patients, four had World Health Organization (WHO) grade I tumors, five had WHO grade II tumors, and in this second group two patients also had recurrent (WHO grade III) meningioma. We also classified the tumors according to our recently developed molecular classification system (Types A, B, and C, with C being the most aggressive). We transplanted all 11 surgical samples into the skull base of immunodeficient (SCID) mice. Only the primary and recurrent tumor cells from one patient-both molecular Type C, despite being WHO grades II and III, respectively-led to the formation of meningioma in the resulting mouse models. We characterized the xenografts by histopathology and RNA-seq and compared them with the original tumors. We performed an in vitro drug screen using 60 anti-cancer drugs followed by in vivo validation. The PDOX models established from the primary and recurrent tumors from patient K29 (K29P-PDOX and K29R-PDOX, respectively) replicated the histopathology and key gene expression profiles of the original samples. Although these xenografts could not be subtransplanted, the cryopreserved primary tumor cells were able to reliably generate PDOX tumors. Drug screening in K29P and K29R tumor cell lines revealed eight compounds that were active on both tumors, including three histone deacetylase (HDAC) inhibitors. We tested the HDAC inhibitor Panobinostat in K29R-PDOX mice, and it significantly prolonged mouse survival ( Meningiomas are not very amenable to PDOX modeling, for reasons that remain unclear. Yet at least some of the most malignant tumors can be modeled, and cryopreserved primary tumor cells can create large panels of tumors that can be used for preclinical drug testing.
Sections du résumé
BACKGROUND
BACKGROUND
Meningiomas constitute one-third of all primary brain tumors. Although typically benign, about 20% of these tumors recur despite surgery and radiation, and may ultimately prove fatal. There are currently no effective chemotherapies for meningioma. We, therefore, set out to develop patient-derived orthotopic xenograft (PDOX) mouse models of human meningioma using tumor.
METHOD
METHODS
Of nine patients, four had World Health Organization (WHO) grade I tumors, five had WHO grade II tumors, and in this second group two patients also had recurrent (WHO grade III) meningioma. We also classified the tumors according to our recently developed molecular classification system (Types A, B, and C, with C being the most aggressive). We transplanted all 11 surgical samples into the skull base of immunodeficient (SCID) mice. Only the primary and recurrent tumor cells from one patient-both molecular Type C, despite being WHO grades II and III, respectively-led to the formation of meningioma in the resulting mouse models. We characterized the xenografts by histopathology and RNA-seq and compared them with the original tumors. We performed an in vitro drug screen using 60 anti-cancer drugs followed by in vivo validation.
RESULTS
RESULTS
The PDOX models established from the primary and recurrent tumors from patient K29 (K29P-PDOX and K29R-PDOX, respectively) replicated the histopathology and key gene expression profiles of the original samples. Although these xenografts could not be subtransplanted, the cryopreserved primary tumor cells were able to reliably generate PDOX tumors. Drug screening in K29P and K29R tumor cell lines revealed eight compounds that were active on both tumors, including three histone deacetylase (HDAC) inhibitors. We tested the HDAC inhibitor Panobinostat in K29R-PDOX mice, and it significantly prolonged mouse survival (
CONCLUSION
CONCLUSIONS
Meningiomas are not very amenable to PDOX modeling, for reasons that remain unclear. Yet at least some of the most malignant tumors can be modeled, and cryopreserved primary tumor cells can create large panels of tumors that can be used for preclinical drug testing.
Identifiants
pubmed: 32517016
pii: cancers12061478
doi: 10.3390/cancers12061478
pmc: PMC7352400
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NINDS NIH HHS
ID : K08 NS102474
Pays : United States
Organisme : NINDS NIH HHS
ID : K08NS102474
Pays : United States
Références
BMC Cancer. 2016 Mar 28;16:253
pubmed: 27020242
PLoS One. 2012;7(12):e52485
pubmed: 23300683
Oncotarget. 2017 Feb 14;8(7):11460-11479
pubmed: 28002790
Neurosurgery. 2007 Apr;60(4):750-9; discussion 759-60
pubmed: 17415213
Neuro Oncol. 2010 Jun;12(6):580-94
pubmed: 20511191
Science. 2013 Mar 1;339(6123):1077-80
pubmed: 23348505
Chin Clin Oncol. 2019 Apr;8(2):17
pubmed: 30943729
Exp Cell Res. 2006 Jul 15;312(12):2358-66
pubmed: 16730707
Nat Rev Cancer. 2013 Dec;13(12):871-82
pubmed: 24263190
Stem Cells. 2008 Jun;26(6):1414-24
pubmed: 18403755
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Eur J Cancer. 2017 Mar;73:9-21
pubmed: 28082204
J Am Soc Nephrol. 2005 Nov;16(11):3247-55
pubmed: 16207825
Cancers (Basel). 2019 Oct 24;11(11):
pubmed: 31652973
Cancer Med. 2017 Jun;6(6):1378-1388
pubmed: 28464467
Oncotarget. 2017 Sep 8;8(50):87455-87471
pubmed: 29152094
Genome Biol. 2014;15(12):550
pubmed: 25516281
Clin Cancer Res. 2006 Aug 1;12(15):4687-94
pubmed: 16899619
Neoplasia. 2002 Jul-Aug;4(4):304-11
pubmed: 12082546
Brain Pathol. 2008 Apr;18(2):172-9
pubmed: 18093250
J Neurosurg. 2000 Feb;92(2):306-14
pubmed: 10659019
Nat Commun. 2017 Feb 14;8:14433
pubmed: 28195122
Nat Commun. 2020 Jan 3;11(1):89
pubmed: 31900397
PLoS One. 2017 May 26;12(5):e0178322
pubmed: 28552950
Animal Model Exp Med. 2019 Feb 20;2(1):58-63
pubmed: 31016288
Nat Genet. 2013 Mar;45(3):285-9
pubmed: 23334667
Neurosurgery. 2009 Jan;64(1):56-60; discussion 60
pubmed: 19145156
Neurosurgery. 1990 Sep;27(3):389-95; discussion 396
pubmed: 2234331
Updates Surg. 2020 Apr 6;:
pubmed: 32253687
Development. 2012 Jun;139(12):2139-49
pubmed: 22573622
Int J Mol Sci. 2017 Aug 31;18(9):
pubmed: 28858204
Neuro Oncol. 2018 Oct 1;20(suppl_4):iv1-iv86
pubmed: 30445539
Int J Cancer. 2010 Dec 15;127(12):2804-14
pubmed: 21351259
Cell Rep. 2018 Mar 27;22(13):3672-3683
pubmed: 29590631
Lancet Oncol. 2017 May;18(5):682-694
pubmed: 28314689
Bioinformatics. 2009 May 1;25(9):1105-11
pubmed: 19289445
Proc Natl Acad Sci U S A. 2019 Oct 22;116(43):21715-21726
pubmed: 31591222
Int J Oncol. 2007 Jul;31(1):5-17
pubmed: 17549400
Int J Oncol. 2008 Nov;33(5):937-47
pubmed: 18949356
J Transl Med. 2015 Jul 15;13:227
pubmed: 26174772
Neurosurgery. 1998 Jan;42(1):130-5; discussion 135-6
pubmed: 9442514
Br J Cancer. 2010 Mar 2;102(5):883-91
pubmed: 20160723
Nucleic Acids Res. 2016 Jul 8;44(W1):W90-7
pubmed: 27141961
Neuro Oncol. 2018 Aug 2;20(9):1185-1196
pubmed: 29982664
Neuro Oncol. 2016 Sep;18(9):1278-87
pubmed: 26951380
Cell. 2019 Sep 5;178(6):1299-1312.e29
pubmed: 31474368
Mol Cancer. 2016 May 04;15(1):32
pubmed: 27145964
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931
Cell Rep. 2017 Nov 14;21(7):1737-1745
pubmed: 29141209
Surg Neurol. 2008 Sep;70(3):295-307; discussion 307
pubmed: 18261772
Nat Genet. 2016 Oct;48(10):1253-9
pubmed: 27548314
Nat Med. 2015 Jun;21(6):555-9
pubmed: 25939062